Back to Search Start Over

Macrophage migration inhibitory factor promotes renal injury induced by ischemic reperfusion

Authors :
Li, Jin H.
Tang, Ying
Lv, Jun
Wang, Xiao H.
Yang, Hui
Tang, Patrick M. K.
Huang, Xiao R.
He, Zhi J.
Zhou, Zi J.
Huang, Qiu Y.
Klug, Joerg
Meinhardt, Andreas
Fingerle-Rowson, Guenter
Xu, An P.
Zheng, Zhi H.
Lan, Hui Yao
Li, Jin H.
Tang, Ying
Lv, Jun
Wang, Xiao H.
Yang, Hui
Tang, Patrick M. K.
Huang, Xiao R.
He, Zhi J.
Zhou, Zi J.
Huang, Qiu Y.
Klug, Joerg
Meinhardt, Andreas
Fingerle-Rowson, Guenter
Xu, An P.
Zheng, Zhi H.
Lan, Hui Yao
Publication Year :
2019

Abstract

Macrophage migration inhibitory factor (MIF) is pleiotropic cytokine that has multiple effects in many inflammatory and immune diseases. This study reveals a potential role of MIF in acute kidney injury (AKI) in patients and in kidney ischemic reperfusion injury (IRI) mouse model in MIF wild-type (WT) and MIF knockout (KO) mice. Clinically, plasma and urinary MIF levels were largely elevated at the onset of AKI, declined to normal levels when AKI was resolved and correlated tightly with serum creatinine independent of disease causes. Experimentally, MIF levels in plasma and urine were rapidly elevated after IRI-AKI and associated with the elevation of serum creatinine and the severity of tubular necrosis, which were suppressed in MIF KO mice. It was possible that MIF may mediate AKI via CD74/TLR4-NF-kappa B signalling as mice lacking MIF were protected from AKI by largely suppressing CD74/TLR-4-NF-kappa B associated renal inflammation, including the expression of MCP-1, TNF-alpha, IL-1 beta, IL-6, iNOS, CXCL15(IL-8 in human) and infiltration of macrophages, neutrophil, and T cells. In conclusion, our study suggests that MIF may be pathogenic in AKI and levels of plasma and urinary MIF may correlate with the progression and regression of AKI.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1201315350
Document Type :
Electronic Resource